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Abstract
Human polyomaviruses (HPyVs) are a growing challenge in immunocompromised patients in view of the increasing number of now 12
HPyV species and their diverse disease potential. Currently, histological evidence of disease is available for BKPyV causing nephropathy
and haemorrhagic cystitis, JCPyV causing progressive multifocal leukoencephalopathy and occasionally nephropathy, MCPyV causing
Merkel cell carcinoma and TSPyV causing trichodysplasia spinulosa, the last two being proliferative skin diseases. Here, the current role of
HPyV in solid organ transplantation (SOT) was reviewed and recommendations regarding screening, monitoring and intervention were
made. Pre-transplant screening of SOT donor or recipient for serostatus or active replication is currently not recommended for any
HPyV. Post-transplant, however, regular clinical search for skin lesions, including those associated with MCPyV or TSPyV, is
recommended in all SOT recipients. Also, regular screening for BKPyV replication (e.g. by plasma viral load) is recommended in kidney
transplant recipients. For SOT patients with probable or proven HPyV disease, reducing immunosuppression should be considered to
permit regaining of immune control. Antivirals would be desirable for treating proven HPyV disease, but are solely considered as adjunct
local treatment of trichodysplasia spinulosa, whereas surgical resection and chemotherapy are key in Merkel cell carcinoma. Overall, the
quality of the clinical evidence and the strength of most recommendations are presently limited, but are expected to improve in the
coming years.
Keywords: Merkel cell carcinoma, nephropathy, polyoma, progressive multifocal leukoencephalopathy, PyVAN, solid organ
transplantation, trichodysplasia spinulosa, virus
Article published online: 29 January 2014
Clin Microbiol Infect 2014; 20 (Suppl. 7): 74–88
Corresponding author: H. H. Hirsch, Transplantation & Clinical
Virology, Department of Biomedicine (Haus Petersplatz), University
of Basel, Petersplatz 10, CH-4003 Basel, Switzerland
E-mail ID: hans.hirsch@unibas.ch
Hot Topics
 Pre-transplant testing of all SOT donors and all SOT
recipients for HPyV-speciﬁc antibody, T-cells or DNA in
urine, blood or other clinical specimens is not recom-
mended, because current data are not sufﬁcient for guiding
organ allocation, risk stratiﬁcation, immunosuppressive
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therapy, screening modalities or prophylactic, preemptive or
therapeutic intervention pre- or post-transplant (BIII).
 For SOT recipients listed for kidney transplantation after
terminal renal failure due to PyVAN in native or trans-
planted kidneys, testing of plasma BKPyV should be consid-
ered and should be undetectable prior to (re-)
transplantation or at least have declined by >2 log10 GEq/
mL compared with documented peak plasma loads (BIII).
 All SOT recipients should have an annual skin and lip
examination by a qualiﬁed health care professional with
experience in diagnosing proliferative and malignant skin
diseases to identify HPyV-associated skin diseases as well as
melanoma and non-melanoma skin cancers (BII).
 Post-transplant routine screening of SOT recipients for any
HPyV DNA (including JCPyV, MCPyV, TSpyV, KIPyV,
WUPyV) in urine, blood or other clinical specimens is not
recommended (with the exception of BKPyV in kidney
transplant recipients), because current data are not sufﬁcient
for risk stratiﬁcation, or for guiding immunosuppressive
therapy, screening modalities, or prophylactic, preemptive
or therapeutic intervention (BIII).
 All kidney transplant recipients should be regularly screened
for BKPyV replication in urine (viruria) or plasma (viraemia)
to identify patients at increased risk of PyVAN (AII).
 In kidney recipients with conﬁrmed (sustained) plasma BKPyV
loads or presumptive or proven PyVAN, maintenance immu-
nosuppression should promptly be reduced in a step-wise
fashion unless other competing risks are imminent (AII).
Introduction
Human polyomavirus (HPyV) species currently encompass 12
members of the genus polyomavirus within the family of
polyomaviridae [1]. The ﬁrst HPyVs were JC polyomavirus
(JCPyV) and BK polyomavirus (BKPyV), both named after the
initials of the patients from whom they were ﬁrst isolated:
JCPyV was detected in brain tissue from a patient with
progressive multifocal leukoencephalopathy (PML) [2,3] while
BKPyV was detected in urine from a kidney transplant patient
with ureteric stenosis shedding ‘decoy cells’ [4,5]. In the past
decade, 10 additional HPyVs have been identiﬁed by different
molecular genetic techniques: the Karolinska Institute (KI-)PyV
and Washington University (WU-)PyV in respiratory secre-
tions of patients with unidentiﬁed cause of pneumonia [6], the
MCPyV in Merkel cell carcinoma and TSPyV in Trichodysplasia
spinulosa, two skin diseases in chronically immunocomprom-
ised patients [7,8], as well as six additional HPyVs, the clinical
role of which still needs to be elucidated [9]. Seroprevalence
studies indicate that HPyVs infect 30–90% of the general
population and are transmitted independently of one another
[7–11]. So far, the mode of transmission has not been resolved
for any HPyV. However, HPyVs are frequently detectable in
different body sites and ﬂuids of healthy immunocompetent
individuals, including skin, hair follicles, saliva, urine, faeces and
respiratory secretions, and can be found in human sewage
[9,11–13]. Thus, these hardy, non-enveloped viruses of 40- to
45-nm diameter are likely to be transmitted by direct
person-to-person contact and by exposure to contaminated
surfaces, foods and water.
Uncovering the respective route of transmission is ham-
pered by the fact that characteristic clinical manifestations of
primary infections have not been identiﬁed for any HPyV,
presumably because of a mostly subclinical course or because
of a clinically unspeciﬁc, for example ﬂu-like, presentation. In
rare cases, primary HPyV infections have been discussed as the
cause of disease manifestations in the central nervous system
(CNS), and in the respiratory, renourinary or gastrointestinal
tract. However, supporting data (e.g. demonstrating serocon-
version) are typically lacking. Evidence of biopsy-proven HPyV
disease is largely conﬁned to immunocompromised patients
such as transplant recipients. Here, we review the role of
HPyV infection, replication and disease (Table 1) in solid organ
transplantation (SOT) patients and provide recommendations
regarding the pre-transplant and post-transplant screening, and
treatment and prevention using the Infectious Diseases Society
of America – United States Public Health Service Grading
System [14].
Diagnostic Aspects
Nucleic acid ampliﬁcation testing (NAT) (e.g. by polymerase
chain reaction) is the key diagnostic tool to detect HPyV
TABLE 1. Working deﬁnitions of virus infection, replication
and disease in transplant patients
Virus infection – evidence of virus exposure
– by detecting speciﬁc immune responses (virus-speciﬁc antibody or
T-cells)
or
– by detecting speciﬁc viral antigens, nucleic acids
Note: latent infection or low-level replication is difﬁcult to distinguish for
persisting viruses (e.g. polyoma-, herpes-, papilloma-, adenoviruses)
Virus replication – evidence of viral replication by at least one of the following
– increasing viral loads
– direct virion antigen detection
– virus isolation by culture
Note: Virus replication without compatible symptoms and signs of disease
may be presymptomatic (e.g. require preemptive treatment).
Probable virus disease – evidence of viral replication above clinically relevant
thresholds, or together with compatible symptoms and signs of viral syndrome
or organ disease, but without histological conﬁrmation
Note: A major contribution of other aetiologies should be excluded.
Proven virus disease – evidence of virus replication plus corresponding
speciﬁc histopathology
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infection and replication with high sensitivity and speciﬁcity in
different specimens [3,5–9]. Because of the widespread
detectability of HPyVs, the clinical signiﬁcance of qualitative
NAT results is difﬁcult to interpret [15]. Instead, quantitative
NAT assays can provide a (semi-)quantitative evaluation of the
viral burden by reporting viral genome loads expressed as
genome equivalents (GEq) per mL of reference specimen
volume or per number of diploid host cells [15,16]. However,
signiﬁcant changes in viral genome load must be greater than
the variation coefﬁcient of the method, which varies for
different analytes and matrices, and also for different assays
and even viral load levels [17,18]. As a ﬁrst approximation, it is
commonly accepted that signiﬁcant differences in viral genome
loads in ﬂuids such as plasma or cerebrospinal ﬂuid must be >1
log10 GEq/mL and >2 log10 GEq/mL in urine samples [19]. For
tissue samples, the viral genome loads may depend on the
amount of tissue and their cell content, which can be
expressed as viral loads per number of diploid host cells using
host cell reference genes or per total DNA content where
150 000 cells correspond to approximately 1 lg DNA.
Because usually not all cells in a tissue sample are infected,
tissue viral loads are probably less robust than viral loads in
ﬂuid samples. Because of the limited inter-laboratory agree-
ment and the current lack of an internationally validated
calibrator for standardization [20], the comparison of serial
patient samples is only considered informative when tested by
the same assay, preferably in the same laboratory.
Urine cytology is used in some kidney transplant (KT) centres
to identify patients shedding ‘decoy cells’. Decoy cells are a
marker of very high urine viral loads, typically ≥7 log10 GEq/mL
as the result of high-level replication in the renourinary
compartment, but do not distinguish between BKPyV and
JCPyV) [21], or may be confused with effects from other
viruses such as adeno- or cytomegalovirus (CMV) [22]. Urine
cytology is inexpensive and requires little infrastructure, but
considerable pre-analytical logistics in the clinics and analytical
laboratory expertise. Prolonged shedding of >2 months and
the presence of tubular casts, inﬂammatory cells in the urinary
sediment, and the detection of three-dimensional PyV aggre-
gates by electron microscopy possibly increases the speciﬁcity
for signiﬁcant renal disease in KT recipients [23]. However,
they have not been examined in larger comparative studies and
their role in screening and preemptive management is
presently undeﬁned [15].
Antibody testing has been initially performed for JCPyV and
BKPyV by haemagglutination inhibition or virus-neutralization.
Currently, however, the most widely used assays are based on
recombinant expression of the major capsid protein VP1, or
parts of the HPyV T-antigens in baculovirus, yeast, E. coli or
diverse non-human and human cell lines. Puriﬁed virus-like
particles (VLPs), VP1-fusion proteins or pseudoviruses then
permit testing for IgG, IgM and IgA activities by ELISA or testing
for neutralization, respectively. There are few data regarding the
role of HPyV serology in SOT, with the exception of BKPyV.
Most KT recipients have been found to be BKPyV IgG
seropositive, but nevertheless may develop high-level viruria,
viraemia and nephropathy [24]. This indicates that BKPyV-spe-
ciﬁc antibodies cannot prevent progression to disease in KT
patients and suggests that virus-speciﬁc T cells are the key to
controlling BKPyV replication. However, transplantation of
kidneys from donors with high BKPyV-speciﬁc antibody titres
into recipients with lowor undetectable antibody titres has been
associatedwith an increased riskof BKPyVviruria and viraemia in
KT recipients [25–28]. Also, increasing antibody responses,
which neutralize speciﬁc BKPyV serotypes, have been detected
in KT patients post-transplant, suggesting that exposure to new
BKPyV serotypes occurs post-transplant in KT patients [29].
These data, together with the identiﬁcation of the same BKPyV
variants in recipients of kidney pairs from the same donors,
suggest that BKPyV in the transplanted kidney allograft is a
relevant, but not the exclusive, source of BKPyV replication and
polyomavirus-associated nephropathy (PyVAN).
Virus-speciﬁc T-cell responses to HPyVs have been studied in
peripheral blood of SOT patients, mostly for BKPyV [30–37],
and to JCPyV, MCPyV and TSPyV in other patient groups [38–
44]. Typically, functional assays are used in quantifying the
number of cytokine-producing T-cells after stimulation with
speciﬁc viral epitopes using enzyme-linked immunospot assay
or intracellular cytokine staining and ﬂow cytometry. Research
data for BKPyV and similar tests for CMV suggest that
abundance of virus-speciﬁc T cells in the peripheral blood is
associated with protection from viral replication and disease
(i.e. showing a good positive predictive value in patients with
stable maintenance immunosuppression) [45,46]. Moreover,
cessation of BKPyV replication was shown to correlate with
reconstitution of BKPyV-speciﬁc T-cell immunity, whereas
ongoing and recurrent BKPyV viraemia was associated with
weak or undetectable T-cell responses [33,34,37,47].
Together, the data suggest that BKPyV-speciﬁc T cells have
an important role in controlling BKPyV replication. However,
these BKPyV-speciﬁc assays are currently limited by poor
negative predictive values (of <50% for subsequent virus
replication and/or disease) even when using the more sensitive
in vitro expansion assay.
HPyV Diseases in SOT Recipients
The key HPyV diseases in SOT are PyVAN because of its high
frequency and detrimental course for the renal allograft in KT
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recipients [5], and PML because of its high morbidity and
mortality [3].
PyVAN is rare in non-kidney SOT, but causes premature
renal failure in 1–14% of KT patients, typically in the ﬁrst
2 years post-transplant [15]. Without intervention, more than
90% of KT patients with PyVAN show a decline in kidney
allograft function, which is followed by graft loss in at least 50%
of cases. Immunosuppression is a major risk factor for BKPyV
replication and development of PyVAN [48–50]. The risk for
BK-PyVAN is increased when lymphocyte-depleting antibodies
or higher cumulative corticosteroid exposure are used for
induction or rejection therapy. A higher risk has also been
reported for tacrolimus-mycophenolic acid combinations com-
pared with cyclosporine-mycophenolic acid, higher tacrolimus
or mycophenolate exposure or mTOR inhibitor-combinations
in large retrospective studies, registry analyses and in prospec-
tive randomized trials [51–54]. Further PyVAN determinants
are related to the recipient (male gender, older age, low or
undetectable BKPyV antibody; low or absent BKPyV-speciﬁc T
cell responses), the donor (recent BKPyV exposure, HLA
mismatch, deceased donation) and the transplant (ischaemia/
reperfusion injury, ureteric stents, acute rejection, retrans-
plantation after graft loss due to PyVAN). However, PyVAN
incidence rates and risk factors vary between different
transplant programmes, and are likely to reﬂect local differ-
ences in organ types and immunosuppression protocols. Other
relevant BKPyV-associated diseases include PyV-associated
haemorrhagic cystitis, ureteric stenosis, pneumonia, encepha-
litis and retinitis, all of which are rare in SOT [5]. Rarely, JCPyV
may also cause PyVAN in KT recipients who have typically no
evidence of relevant BKPyV replication [3,21,55]. Importantly,
JCPyV viraemia is much lower or undetectable in JC-PyVAN,
impeding its use as a convenient surrogate marker as
established for BK-PyVAN high-level viruria, leaving only high
urine JCPyV loads as an index of suspicion. [21].
Progressive multifocal leukoencephalopathy is caused by JCPyV
and has been reported in practically all SOTs, including KT,
heart transplant (HT), lung transplant (LuT), liver transplant
(LiT) and kidney-pancreas transplant (KPT) recipients, showing
a high mortality of more than 80% [3,56]. The incidence rates
of PML in SOT are not well deﬁned, but a recent study of HT
and LuT recipients estimated 1.29 PML cases per 1000
post-transplant patient years [57]. By comparison, PML was
estimated to occur in 2.4 per 1000 patient years in HIV-AIDS
patients before availability of combination antiretroviral ther-
apy [58], and 2.1 to almost 10 per 1000 patient years in
multiple sclerosis patients treated with natalizumab [59]. The
rareness of PML in SOT has impeded the identiﬁcation of risk
factors and the development of a sensitive and speciﬁc
biomarker for screening comparable to BKPyV viraemia [60–
62]. This renders PML typically a clinical diagnosis at an
advanced stage of considerable brain damage [3].
Trichodysplasia spinulosa, also called trichodysplasia of immu-
nosuppression, pilomatrix dysplasia or calcineurin
inhibitor-associated folliculodystrophy, is a rare prolifera-
tive-cytopathic skin disease with detectable PyV particles in
inner root hair follicles of immunocompromised individuals
[8]. Clinically, the affected patients develop papules of
thickened skin and small hair-like protrusions called spiculae
most prominently seen in the forehead, nose and ears,
together with often circumscribed alopecia (e.g. of the
eyebrows). The affected patients belong to all age groups,
and frequently have a history of leukemia, chemotherapy or
transplantation. The spiculae must be distinguished from other
digitate hyperkeratoses [63]. There are no reliable data about
the rates and risk factors of Trichodysplasia spinulosa in SOT,
which is likely to occur in less than 1 per 1000 patient years
post-transplant, but the disease is probably under-reported.
Most cases in SOT have been described in KT recipients,
followed by HT and LuT recipients. However, it is unclear
whether or not renal failure and KT per se predispose to
Trichodysplasia spinulosa, or if this simply reﬂects the higher
number of immunocompromised KT patients with long-term
graft survival and corresponding follow-up.
Merkel cell carcinoma is a rare aggressive cancer that occurs
in 0.24 – 0.35 cases per 100 000 patient years [7,64]. The
initially often solitary purplish lesion is typically located on
sun-exposed skin of elderly white, preferentially immunocom-
promised individuals, including SOT and HIV patients. The
vowels of the alphabet AEIOU have been proposed as acronym
to summarize characteristic clinical features of Merkel cell
carcinoma [65]: Asymptomatic initially, Expanding rapidly in <
3 months, Immunocompromised, Older than 50 years of age,
UV-exposed site [65]. MCPyV has been detected in the
majority of proven cases and is classiﬁed as a class 2A
carcinogen [66]. However, the MCPyV genomes are altered
due to different chromosomal integration events [66]. This
permits expression of early viral gene regions such as the small
tumour antigen, but disrupts expression of late viral gene
regions, and hence abrogates the (cyto-)lytic viral replication
cycle [67,68]. According to the HPyV pathology patterns
proposed previously, Merkel cell carcinoma is a non-replicative
viral pathology [69]. However, affected patients often have
high antibody levels not only to epitopes of the tumour
antigens, but also to the capsid proteins [70]. This suggests that
signiﬁcant MCPyV replication must have occurred at an earlier,
possibly pre-disease seeding stage. Interestingly, patients with
higher antibody titres have been associated with better clinical
outcomes, implicating antibody titres as markers of better
virus-speciﬁc immune responses and outcome [71,72].
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Respiratory tract infections have been associated with the
detection of KIPyV and WUPyV in respiratory samples, but
evidence of proven pathology is lacking. The detection rates of
KIPyV and WUPyV range from 1% to 16% and 0.5% to 8%,
respectively, in various studies of healthy individuals and
patients with respiratory symptoms [6]. No comprehensive
data are currently available from SOT, possibly with the
exception of LuT recipients [73]. KIPyV and WUPyV were
detected in 9.2% and 12.3% of 66 transbronchial biopsies,
respectively, with a low tissue viral load around 1200 GEq per
150 000 diploid cell equivalents [74]. The detection of KIPyV
and WUPyV was not associated with clinical and histopatho-
logical ﬁndings, which included acute respiratory insufﬁciency,
interstitial and organizing pneumonia, and acute and chronic
rejection. Data from allogeneic haematopoietic stem cell
transplant recipients suggest a frequent colonization in asymp-
tomatic patients, but also a possible (co-)factorial role in
wheezing and impaired lung function [75]. Similar to allogeneic
haematopoietic stem cell transplantation [76], therefore, no
recommendation on screening, prevention and treatment of
KIPyV and WUPyV can be given at this time for SOT patients.
For the remaining HPyVs, no deﬁnitive disease association has
been identiﬁed, including for SOT patients. Thus, HPyV6 and -7
are frequently detected on the skin of healthy and immuno-
compromised patients, with rates ranging from 10% to more
than 30%, HPyV9 has been detected in blood and rarely on skin,
and HPyV10 and its closely related variants MWPyV, MXPyV,
St-Louis PyV and HPyV12 have been found in faecal samples of
individuals with and without gastrointestinal disease [9,77].
Therefore, the role of these HPyVs in SOT is presently unclear
and no recommendations for screening for and diagnosis of
these HPyVs can be made at this time.
Pre-transplant HPyV Assessment of SOT
Donors and Recipients
The recommendations regarding the pre-transplant evaluation
of SOT donors and recipients with respect to HPyV serology,
NAT and virus-speciﬁc T-cell tests are summarized in Table 2.
In general, no pre-transplant screening is recommended,
except for speciﬁc patients that are listed for kidney
transplantation after loss of renal function due to PyVAN.
Post-transplant HPyV Assessment and
Management of SOT Recipients
The recommendations regarding the post-transplant screening
for HPyV in SOT recipients are summarized in Table 3, with
the exception of BKPyV in KT recipients. The recommenda-
tions for post-transplant treatment presently focus on patients
with probable or proven HPyV disease, while presently
discouraging general HPyV screening modalities (except for
BKPyV in KT recipients), because of insufﬁcient evidence of
beneﬁt.
KT recipients
Screening. Post-transplant screening is currently only recom-
mended for BKPyV in KT patients as summarized in Table 4.
International guidelines recommend a minimal screening for
TABLE 2. Recommendations for HPyV-speciﬁc pre-trans-
plant testing of SOT donors and recipients
Pre-transplant testing of all SOT donors and all SOT recipients for any
HPyV DNA in urine, blood or other clinical specimens is not recommended,
because current data are not sufﬁcient for guiding organ allocation, risk
stratiﬁcation, immunosuppressive therapy, screening modalities or prophylactic,
preemptive or therapeutic intervention pre- or post-transplant (BIII)
For SOT recipients listed for kidney transplantation after terminal renal failure
due to PyVAN in native or transplanted kidneys, testing of plasma BKPyV
should be considered and should be undetectable prior to (re-)transplantation
or at least have declined by at least >2 log10 GEq/mL compared with documented
peak plasma loads (BIII)
Pre-transplant HPyV serology of SOT donors or SOT recipients is not
recommended, because current data are not sufﬁcient for guiding organ
allocation, risk stratiﬁcation, immunosuppressive therapy, screening modalities,
or prophylactic, preemptive or therapeutic intervention pre- or
post-transplant (BIII)
Pre-transplant testing of HPyV-speciﬁc T-cell responses in peripheral blood of
SOT donors or SOT recipients is not recommended, because current data
are not sufﬁcient for guiding organ allocation, risk stratiﬁcation,
immunosuppressive therapy, screening modalities, or prophylactic, preemptive
or therapeutic intervention modalities in SOT recipients (BIII)
TABLE 3. Recommendations for post-transplant evalution
for HPyV in SOT recipients
All SOT recipients or the legal representative in the case of children should be
counselled to perform self-examination of skin and lips to identify and report
new skin lesions to a health care provider (BIII)
All SOT recipients should have an annual skin and lip examination by a qualiﬁed
healthcare professional with experience in diagnosing proliferative and
malignant skin diseases to identify HPyV-associated skin diseases as well as
melanoma and non-melanoma skin cancers (BII)
Post-transplant routine screening of SOT recipients for any HPyV DNA (including
JCPyV, MCPyV, TSpyV, KIPyV and WUPyV) in urine, blood or other clinical
specimens is not recommended (with the exception of BKPyV in KT recipients),
because current data are not sufﬁcient for risk stratiﬁcation, or for guiding
immunosuppressive therapy, screening modalities, or prophylactic, preemptive
or therapeutic intervention (BIII)
Post-transplant routine screening of SOT recipients for any HPyV-speciﬁc
antibody responses (including BKPyV, JCPyV, MCPyV, TSpyV, KIPyV and
WUPyV) is not recommended, because current data are not sufﬁcient for
risk stratiﬁcation, or for guiding immunosuppressive therapy, screening
modalities, or prophylactic, preemptive or therapeutic intervention (BIII)
For SOT patients with probable HPyV disease, tissue specimens should be
obtained for histopathology and speciﬁc immunohistochemistry, including
staining for HPyV proteins encoded in the early and late viral gene region
(e.g. large or small T-antigen, VP1 capsid proteins) to obtain the diagnosis
of proven HPyV disease (BIII)
Testing tissue specimens for HPyV DNA by NAT cannot substitute for
immunohistochemistry, but may be considered as an adjunct tool for diagnosis,
if immunohistochemistry is not possible (BIII)
HPyV DNA in tissue specimens should be reported as genome equivalents per
diploid cells to permit semi-quantitative comparison of the results with those
from unaffected tissues (BIII)
In the absence of speciﬁc histopathology, the presence may be determined by
HPyV genome alterations that have been consistently linked to, and may
independently support, the diagnosis of a HPyV disease (e.g. rearrangements
of the non-coding control region, point mutations and truncations of the early
and late viral gene region) (BIII)
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BKPyV replication of at least once every 3 months in the ﬁrst
2 years post-transplant, then annually thereafter for 5 years,
and in the event of an unexplained serum creatinine rise or after
treatment for acute rejection [15,16,19]. However, it is
advisable to adapt the screening algorithm according to
centre-speciﬁc characteristics (such as very low or very high
PyVAN incidence, paediatric cohorts and sensitized recipients).
Speciﬁcally, as de novo BKPyV replication preferentially occurs
within the ﬁrst 6 months post-transplant, and most cases of
PyVAN occur in the ﬁrst year post-transplant, intensiﬁed
screening by monthly sampling in the ﬁrst 6 months is recom-
mended, followed by decreasing frequency thereafter [15,78].
BKPyV viraemia has a positive predictive value of 30–50% for
proven PyVAN [79], that increases to more than 90% in the
presence of very high plasma BKPyV loads, appearance of
genomic BKPyV variants with rearrangements in the non-coding
control regions [80], or when renal dysfunction is present.
The sensitivity of PyVAN histology may be increased by
adequately sized biopsies, use of larger biopsy needles (e.g.
gauge 18) and the presence of renal medulla. Nevertheless,
kidney allograft biopsies may be falsely-negative at an estimated
rate of 10–30% in early stages of PyVAN [81]. Hence, kidney
recipients with sustained plasma BKPyV loads above 1000
GEq/mL are at risk and have been diagnosed as having
‘presumptive’ PyVAN, when increasing to more than 4 log10
Geq/mL [15,19]. The shorter window period observed
between BKPyV viraemia and PyVAN has suggested monthly
monitoring as the preferred strategy in some centres,
particularly those screening plasma directly. Anecdotal cases
of kidney recipients with histologically proven PyVAN found
negative for BKPyV viraemia have been reported [82]. In these
cases, methodological issues need to be ruled out [83,84] as
well as the presence of a rare case of JC-PyVAN, which
typically shows low or undetectable plasma JCPyV loads
despite persisting high urine JCPyV loads >7 log GEq/mL
[21,55]. In many cases, JCPyV-mediated PyVAN is cleared after
reducing immunosuppression [21]. No universal screening for
JCPyV can be recommended given the rarity of this condition,
but persisting high urine JCPyV loads in the absence of BKPyV
loads may raise suspicion [15,21].
Screening for BKPyV replication can also be performed by
testing urine for high-level BKPyV viruria, which precedes
viraemia and nephropathy by 4 to 12 weeks, and can
effectively rule out PyVAN due its high negative predictive
value [24]. Urine screening is non-invasive and relatively
inexpensive when searching for ‘decoy cells’ by conventional
cytology. However, the low positive predictive value for
PyVAN and unreliable clearance kinetics limit the use of viruria
as a tool to guide therapeutic intervention. A higher positive
predictive value has been reported when urine BKPyV was
tested by the VP1 mRNA transcripts [85] or through electron
microscopy evaluation of three-dimensional viral aggregates
[86]. However, the latter approaches require expertise and
EM instrumentation not widely available, and. Moreover,
independent prospective data are not available to guide
recommendations on their clinical utility, particularly regarding
early, preemptive management. Thus, a positive urine result
should be followed-up by testing for plasma BKPyV loads to
identify patients with presumptive PyVAN and follow their
response to intervention.
Prophylaxis and treatment of probable and proven PyVAN. Inter-
ventions for BKPyV replication and PyVAN potentially encom-
pass prophylactic, preemptive and therapeutic modalities.
There are no BKPyV-speciﬁc antiviral drugs for prophylaxis
or treatment, but the use of ﬂuoroquinolones such as
ciproﬂoxacin and levoﬂoxacin after kidney transplantation
has been associated with a reduced frequency of BKPyV
replication in limited retrospective studies and case series [87–
89]. The use of mTOR inhibitors has been associated with
reduced BKPyV events in registry studies and in retrospective
analyses, but a general recommendation must be balanced
against the overall graft function and outcome [52,90,91].
However, the data are currently insufﬁcient to assess efﬁcacy,
side-effects including bacterial resistance and Clostridium difﬁcile
colitis, costs and the resulting cost–beneﬁt ratio before speciﬁc
recommendations for or against their use can be made
(Table 5). Intravenous immunoglobulin preparations have been
shown to contain BKPyV-speciﬁc antibodies that increase in
KT patients with BKPyV replication and PyVAN [92–95], but
their role in prophylaxis and treatment is currently unresolved
[96,97]. Early detection of BKPyV replication and disease
seems to be important for improved outcomes. Prospective
studies show that progression to PyVAN can be effectively
TABLE 4. Recommendations for post-transplant BKPyV diag-
nostic testing of kidney transplant recipients
All kidney transplant recipients should be regularly screened for BKPyV
replication in urine (viruria) or plasma (viraemia) to identify patients at
increased risk of PyVAN (AII)
Screening plasma for BKPyV loads is recommended monthly in the ﬁrst
6 months post-transplant, followed by 3-monthly screening until 2 years
post-transplant (AII)
Testing urine for signiﬁcant BKPyV replication may be an alternative modality
by identifying ‘decoy cells’, PyV aggregates, BKPyV VP1 mRNA or signiﬁcant
urine BKPyV DNA loads of ≥7 log 10 GEq/mL, but positive cases should be
followed-up by quantifying plasma BKPyV loads (BII)
Testing plasma for BKPyV loads is recommended to guide therapeutic
interventions for kidney transplant patients with probable (presumptive) or
proven PyVAN (AII)
Testing plasma for BKPyV loads is recommended for KT patients having an
unexplained serum creatinine rise, after treatment of acute rejection, or
undergoing protocol biopsies (BIII)
In the absence of an international calibrator, plasma BKPyV load data should
be compared by the same NAT assay, preferably in the same laboratory,
which is operated according to quality assurance programmes and certiﬁed
for transplantation diagnostics (BIII)
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and safely hindered using a preemptive reduction in
immunosuppression [50,98–101]. However, supporting data
do not originate from randomized treatment trials.
Two different immunosuppression reduction protocols, or
their combination, have been proposed to treat conﬁrmed
(sustained) BKPyV viraemia and ‘presumptive’ PyVAN
(Table 6). One approach ﬁrst considers reducing calcineurin
inhibitors (CNI) by 25–50% in one or two steps [36],
followed by reduction/discontinuation of the anti-metabolite
at a later time [98–100], while the other reduces/discontinues
the anti-metabolite, and only subsequently the CNI [50].
Alternatively, the concomitant reduction of both CNI and
anti-metabolite has been reported [100]. All strategies appear
safe in the short term at 1 year of follow-up, showing 4–14%
subsequent acute rejections, all of which were responsive to
steroid therapy. Efﬁcacy was demonstrated in both adult and
paediatric kidney recipients by clearance of plasma BKPyV
loads within weeks to a few months after intervention
(Table 6). However, despite the preemptive timing of reduc-
ing immunosuppression, progression to histologically proven
PyVAN cannot be completely prevented, as demonstrated by
protocol biopsies [78,99,100]. These cases were typically
associated with higher plasma BKPyV loads and required
multiple steps of immunosuppression reduction, and longer
times until clearance of viraemia [99]. Although standard
operating procedures should be deﬁned in each transplant
centre, the decisions should integrate individual patient
factors and CNI trough levels. The effect of immunosuppres-
sion minimization on long-term outcome has been examined
in one study [101], but remains to be assessed for other
approaches.
Minimization of immunosuppression, according to the prin-
ciples described for the preemptive strategy, is also themainstay
of treatment for proven PyVAN. In the latter case, a more
aggressive approach to immunosuppression reduction may be
required, targeting drug levels below the lower end of the
therapeutic range [15,16]. Alternatively to immunosuppression
reduction, a switch from tacrolimus to low-dose cyclosporine A
and from mycophenolic acid to an mTOR inhibitor, preferen-
tially with simultaneous CNI reduction, has also been employed
in small case series with some success. Other treatment
attempts such as cidofovir, leﬂunomide, intravenous immuno-
globulins or ﬂuoroquinolones, have been variably employed. So
far, no randomized trial has demonstrated the superior efﬁcacy
TABLE 5. Recommendations for prophylaxis and treatment
of probable and proven polyomavirus-associated nephropa-
thy in kidney transplant recipients
Based on the presently available data, administration of ﬂuoroquinolones,
mTOR inhibitors and intravenous immunoglobulins is not recommended as
prophylaxis against BKPyV replication and disease in kidney transplant
patients (CIII)
In kidney recipients with conﬁrmed (sustained) plasma BKPyV loads or
presumptive PyVAN, maintenance immunosuppression should promptly
be reduced in a step-wise fashion unless other competing risks are
imminent (AII)
In kidney transplant patients with proven PyVAN, maintenance immunosup-
pression should promptly be reduced in a step-wise fashion unless other
competing risks are imminent (AII)
Presently, a speciﬁc immunosuppression minimization strategy can not be
recommended, but may consist of reducing the calcineurin inhibitor, and/or
reducing and/or discontinuing the antiproliferative drug, switching
immunosuppressive drugs, or a combination thereof (CIII)
Kidney transplant patients undergoing minimization of maintenance
immunosuppression should be followed by measuring at least once- to bi-weekly
serum creatinine concentration to estimate renal allograft function and
plasma BKPyV loads to identify clearance of viraemia (BII)
Kidney allograft biopsy is not routinely recommended in patients in whom
immunosuppression has been reduced for treating probable or proven
PyVAN and renal allograft function is stable (AII)
Kidney allograft biopy is recommended when renal allograft function
signiﬁcantly decreases from baseline to guide further treatment decisions
regarding immunosuppression minimization or treatment of acute
rejection (AII)
Based on the currently available data, administration of cidofovir, leﬂunomide,
ﬂuoroquinolones, mTOR inhibitors or intravenous immunoglobulins is not
recommended as sole or adjunct treatment of kidney transplant recipients
with probable or proven PyVAN (BIII)
TABLE 6. Treatment by reduced immunosuppression in kidney transplant patients with presumptive or proven polyoma-
associated nephropathy
Brennan et al. 2005[50] Ginevri et al. 2007[98] Schaub et al. 2010[99] Sood et al. 2012[100]
Patients Adult (n = 200) Paediatric (n = 52) Adult (n = 203) Adult (n = 240)
BKPyVviraemia n (%) 23 (12) 13 (21) 38 (19) 65 (27)
28 (12.5) with plasma
BKPyV load >4log Geq/mL












Intervention Step 1: discontinue
azathioprine or MMF
Step 2: reduce CNI
Step 1: reduce CNI
Step 2: reduce or
discontinue MMF
Step 1: reduce CNI
Step 2: reduce or
discontinue MMF
Step 1: reduce CNI
and reduce MMF
Step 2: repeat
Outcome at 1 year
Clearance of viraemia, % 95 100 92 80
Time to clearance (range) 1.8 months (7–213) 2 months (1–8) 4.4 months (1–22) 6–12 months
Acute rejection, n (%) 1 (4.3) 0 (0) 3 (8.6) 4 (14.3)
Graft loss None None None 1
Signiﬁcance of bold is just general emphasis as these are the key results.
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of any combined approach over immunosuppression reduction
alone [102].
The use of mTOR inhibitors has been linked to a reduced
rate of BKPyV events in large registry studies and in
single-centre observations [103]. Prospective studies are
underway evaluating the effect of mTOR inhibitors on BKPyV
replication as a secondary endpoint. Virus transmission from
the BKPyV seropositive graft to a seronegative recipient could
theoretically be prevented or limited by administration of
speciﬁc intravenous immunoglobulins. However, no speciﬁc
immunoglobulin or BKPyV vaccine has been developed. A role
of ﬂuoroquinolones was suggested by in vitro studies [104], but
retrospective clinical studies showed variable results [87,89].
Randomized, prospective studies are ongoing; these may clarify
the role of quinolones in preventing BKPyV viraemia and
PyVAN [88].
Histopathology. The recommendations regarding the histolog-
ical diagnosis of PyVAN in SOT recipients are summarized in
Table 7. As discussed, the focal nature of PyVAN may result in
sampling errors in 10–30% of cases [81]. Hence, a negative
biopsy does not rule out PyVAN, particularly in the early
stages. Sampling of medulla reduces the chance of a false-neg-
ative biopsy. For immunohistochemistry, a cross-reacting
monoclonal antibody directed against the large T-antigen of
the Simian virus 40 (clone PAb 416, Calbiochem) is commonly
used. There is considerable inter-laboratory variation in
staining intensity and assessment of percentage of infected
cells, but the binary classiﬁcation of biopsies into virus-positive
and negative is fairly reliable.
Standardized assessment and reporting is suggested to
improve consistent biopsy readings across multiple institu-
tions. Classiﬁcation of PyVAN into categories PyVAN-A, -B
and -C within the same institution is reasonably reproducible
(j = 0.47) [105]. As most biopsies belong to class B, reporting
of subgroups B1, B2 and B3 deﬁned by the increasing
percentage of biopsy area affected should be considered
(Table 8). More recently, the 2009 Banff conference formu-
lated a working proposal wherein stage A and B were deﬁned
by the extent of BKPyV-mediated cell injury. In this system, an
identical stage can be assigned to biopsies that differ markedly
in the degree of inﬂammation, and hence differ in prognosis
[106]. However, inﬂammation and extent of ﬁbrosis and
tubular atrophy at diagnosis may be the most important
predictors of a poor outcome.
Intimal arteritis, glomerulitis and peritubular capillary C4d
deposits are histologic criteria that help to differentiate acute
rejection from PyVAN. Tubulitis is not a reliable discriminating
parameter, even if present away from areas of viral cytopathic
effect. MHC class II upregulation by the tubular epithelium is
no longer considered a marker speciﬁc for rejection as it also
occurs in the context of viral replication [107]. Occasionally,
other viruses such as JCPyV, cytomegalovirus and adenovirus
may result in viral inclusions. Speciﬁc immunohistochemistry
for the respective viral antigens is needed to conﬁrm these
other diagnoses.
The incidence of acute T-cell mediated rejection (ACR)
after reduction of immunosuppression is approximately 10%.
Kidney biopsies are difﬁcult to interpret during this phase.
Morphological criteria for resolving PyVAN and T-cell-medi-
ated rejection overlap, and the differential diagnosis is
facilitated by careful clinical correlation and attention to serial
trends in serum creatinine and viral loads in plasma and then
urine [15,107]. Analyzing T-cell speciﬁcity by next generation
sequencing of T-cell receptor usage might provide a future tool
in the differential diagnosis [108]. In general, response to
steroids is seen in only a third to a half of biopsies that
otherwise satisfy Banff criteria for acute rejection [109,110].
Clinical management in this setting is uncertain until better
diagnostic criteria are developed and effective anti-BKPyV
drugs become available.
Non-kidney SOT recipients
The clinical signiﬁcance of BKPyV replication in non-kidney
SOT recipients is less clear. In a prevalence study comparing
156 consecutive KT, HT or LiT recipients, BKPyV viruria was
found in 26.5%, 25.5% and 7.8%, respectively, of the patients.
BKPyV viraemia was found in 12.2% of KT recipients and 7% of
HT recipients, but not in LiT recipients, and no disease
attributed to BKPyV was seen [111]. Cases of PyVAN have
been observed in non-kidney SOT recipients, albeit rarely. In a
recent review, nine non-kidney transplant patients with
PyVAN were described (six HT, two LuT and one PT). Five
patients received triple immunosuppression consisting of
tacrolimus, mycophenolate and prednisone. PyVAN was
TABLE 7. Histological diagnosis of polyomavirus-associated
nephropathy in kidney and non-kidney SOT recipients
For a histological diagnosis, a minimum of two kidney biopsy cores, preferably
containing medulla tissues, is recommended in order to reduce the rate of
false-negative results (BII)
The diagnosis of proven PyVAN requires compatible cytopathic changes in renal
tubular cells and demonstration of PyV replication by immunohistochemistry
or in-situ hybridization (AII)
The histological ﬁndings of PyVAN should be semi-quantitatively assessed using
proposed criteria to systematically capture the extent of viral, inﬂammatory
and ﬁbrotic changes as markers of prognosis (BII)
JCPyV should be considered as aetiological agent if biopsies show histological
signs of intranuclear inclusions, interstitial inﬁltrates and tubulitis and SV40
large T-antigen-positive immunohistochemistry in renal tissue, but undetectable
viremia (BIII)
Other viral agents such as human adenovirus and cytomegalovirus should
be considered if biopsies show histological signs of intranuclear inclusions,
interstitial inﬁltrates and tubulitis, but absence of conﬁrmatory
immunohistochemistry in renal tissue (BIII)
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diagnosed at a median of 21 months after transplantation
(range 13–25) and ﬁve patients eventually required dialysis
[112]. Where administered, there was little response to
intravenous cidofovir. The poorer prognosis of PyVAN in
non-kidney transplant recipients may be related to the fact that
the diagnosis was made at a late stage of signiﬁcant functional
impairment, the difﬁculty in sufﬁciently reducing immunosup-
pression without causing life-threatening rejections, and a
delayed recovery of BKPyV-speciﬁc immunity. Therefore, in
non-kidney SOT patients with declining renal function, testing
for BKPyV viremia should be considered early in the diagnostic
work-up to identify patients with presumtpive PyVAN.
HT recipients. Studies in HT recipients report rates of BKPyV
viruria and viraemia of 11–25% and 7–21%, respectively [113–
115]. BKPyV viraemia is an early event after HT as 83%
occurred during the ﬁrst 3 months post-transplant. BKPyV
replication in urine and blood was associated with a higher rate
of mild renal failure (p = 0.018). However, only isolated cases
of proven PyVAN have been reported in HT recipients [116–
126]. Accordingly, most centres do not routinely screen for
BKPyV infection in HT recipients.
LuT recipients. A prospective longitudinal study performed in
50 LuT recipients over the course of 17 months detected
BKPyV, JCPyV or SV40 in 31/50 (62%) of the patients’ urine
samples at least once [127]. BKPyV was present in 16/50 (32%)
of the patients but all blood samples were negative. There was
no signiﬁcant association between acute rejection and patients
who shed polyomavirus but patients with shedding had a
worse survival. However, PyVAN leading to terminal renal
failure and haemorrhagic cystitis have been reported in a small
number of adult and paediatric LuT recipients [128–130].
PyVAN was detected in a 67-year-old female recipient
60 months after LuT [112]. Recently, a case of BKPyV-asso-
ciated cancer has been reported in a paediatric LuT recipient
who ﬁrst was diagnosed with PyVAN at 2 years post-trans-
plant leading to end-stage renal failure and then was diagnosed
with ductus Bellini carcinoma of the native kidney [131].
LiT recipients. BKPyV viruria was detected in 7.8–21% and
viraemia ranged from 4% to 18% of LiT recipients
[111,114,115,132–135]. BKPyV viraemia occurred mostly in
the ﬁrst 3 months and was more common in patients with
recent rejection episodes. No relationship between BKPyV
replication and maintenance immunosuppression was
observed. In one study, three patients with sustained BKPyV
viraemia developed renal insufﬁciency, but PyVAN was not
histologically conﬁrmed. One of the patients died of multi-
organ failure with non-identiﬁed viral inclusions in the liver
biopsy and a persistent and extremely high BKPyV viral load
[132].
Treatment of other HPyV disease in SOT recipients
Progressive multifocal leukoencephalopathy (PML) is clinically
suspected when facing new-onset progressing CNS deﬁcits
(such as motor weakness, speech abnormalities, cognitive
deﬁcits, visual ﬁeld deﬁcits and ataxia) and compatible features
on MRI studies (such as hypointense T1-weighted lesions that
appear hyperintense on T2-weighted lesions or ﬂuid-attenu-
ated inversion recovery (FLAIR) sequences) [3,136]. Typically,
the affected persons have abnormalities of the immune system,
TABLE 8. Histological patterns of polyomavirus-associated nephropathy
Pattern Description Extent of biopsy core Graft function Risk of graft loss
PyVAN-A
Viral cytopathic changes Mild Variable (typically <25%) Mostly baseline <10%
Interstitial inﬂammation Minimal ≤10%
Tubular atrophy Minimal ≤10%
Interstitial ﬁbrosis Minimal ≤10%
PyVAN-B *
Viral cytopathic changes Variable Variable (often 11 – >50%) Mostly impaired 50%
Interstitial inﬂammation Signiﬁcant 11 – >50%
Tubular atrophy Mild/moderate <50%
Interstitial ﬁbrosis Mild/moderate <50%
PyVAN-B1
Interstitial inﬂammation Moderate 11–25% Slightly above baseline 25%
PyVAN-B2
Interstitial inﬂammation Signiﬁcant 26–50% Signiﬁcantly impaired 50%
PyVAN-B3
Interstitial inﬂammation Extensive >50% Signiﬁcantly impaired 75%
PyVAN-C
Viral cytopathic changes Variable Variable Signiﬁcantly impaired
progressive failure
>80%
Interstitial inﬂammation Variable Variable
Tubular atrophy Extensive >50%
Interstitial ﬁbrosis Extensive >50%
*Subclassiﬁcation of PyVAN-B into categories B1, B2 and B3 was initially proposed by Drachenberg et al [81]. Using both inﬂammation and tubular atrophy, biopsies with >50%
involvement were designated B3. However, tubular atrophy >50% usually correlates with interstitial ﬁbrosis >50%, which is used to deﬁne PyVAN-C. For simplicity, it is suggested
that subclassiﬁcation PyVAN-B be based entirely on inﬂammation, which is an important and independent predictor of outcome [106].
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but the disease has been detected in presumably immuno-
competent individuals. The strength of the diagnosis is
reﬂected in the diagnostic criteria: probable PML is virolog-
ically conﬁrmed when JCPyV DNA is detected in the CSF,
whereas proven PML requires histological conﬁrmation of
demyelination and the detection of JCPyV replication by
immunohistochemistry or in situ hybridization in brain tissues
(Table 9).
There is no established antiviral treatment for PML and
mounting a JCPyV-speciﬁc immune response to (re-)gain
control over JCPyV replication in the CNS is the key objective
[137,138]. In HIV-AIDS patients with PML or in multiple
sclerosis patients with PML after natalizumab use, this can be
achieved in part by starting combination antiretroviral therapy
or discontinuing and removing natalizumab by plasma
exchange, respectively. However, in SOT recipients, treatment
is limited by acute rejection and subsequent graft loss. For KT
or PT patients, decreased or discontinued immunosuppressive
medication, which leads to return to dialysis or insulin
substitution, is a potentially viable option [139], whereas this
is not the case for HT, LuT and LiT. Recently, a case of PML in
an HSCT patient was treated with donor-derived JCPyV-spe-
ciﬁc T cells [38], suggesting the possibility that immune control
may be enhanced by autologous T-cell therapy in SOT patients,
most likely still requiring reduced immunosuppression.
Currently, there are no data supporting recommendations
about treatment of PML in SOT patients. Whenever possible,
therefore, SOT patients with probable or proven PML should
be enrolled in appropriate clinical treatment trials, and/or
clinical experts should be consulted in individual cases.
Antiviral treatments are desirable because they potentially
should limit the cytopathic damage caused by JCPyV replication
and thereby extend the window for immune recovery [3].
Because of the potential (co-)role of serotonin receptors in
JCPyV infection, some experts recommend treatment with
mirtazapine, starting with 15 mg per day then increasing to the
highest possible dose of, for example, 45 mg per day [140–
142]. However, data from clinical trials are lacking. Meﬂoquine
is not effective in clinical trials and has signiﬁcant side-effects,
including in the CNS, which argue against its clinical use [143].
Cytarabine does not cross the intact blood-brain barrier and
has not been effective in a randomized clinical trial of PML in
HIV-AIDS despite intrathecal administration [144].
Similarly, intravenous cidofovir has not been shown to be
effective in retrospective and prospective studies of HIV-AIDS
patients with PML over antiretroviral therapy alone [145,146].
However, intravenous cidofovir has been studied as prophy-
laxis and treatment for cytomegalovirus retinitis, with some
evidence of efﬁcacy at 5 mg/kg body weight in studies
GS-93-105, -106 and -107 as discussed [147–149]. Cidofovir
is unlikely to cross the intact blood-brain barrier efﬁciently
without organic anion transporters. These are present in the
eye and the renal tubulus, contributing to uveitis/iritis and
renal toxicity. Other side-effects include neutropenia, meta-
bolic acidosis and pancreatitis [148]. However, the blood-brain
barrier may be locally impaired in SOT recipients, especially
when there are signs of contrast-enhancement on MRI.
CMX001 (recently called brincidofovir), an oral lipid conjugate
of cidofovir, has shown 400-fold higher in vitro efﬁcacy against
JCPyV [150], and reaches higher intrathecal concentration in
animal models. Recent clinical studies suggest efﬁcacy against
cytomegalovirus replication in allogeneic HSCT recipients
when dosed at 100 mg per os twice weekly, without renal
toxicity, but with diarrhoea as a major adverse event [151].
However, there are as yet no clinical trials demonstrating its
potential clinical efﬁcacy in PML. Therefore, the current
management of probable or proven PML in SOT patients
remains a clinical challenge (Table 9). Similar considerations
must also be applied to patients with other JCPyV-associated
diseases such as granule cell neuronopathy, encephalopathy or
nephropathy [3].
Merkel cell carcinoma is diagnosed on clinical grounds and the
key predictor of outcome is invasiveness and metastasis into
the local lymph node and disseminated disease [7,152,153].
Treatment is stage dependent and requires the assessment of
whether or not the disease is local or has metastasized in
regional lymph nodes as assessed macroscopically, microscop-
ically by sentinel lymph node biopsy and/or by [18] F-PET
computed tomography [153], or has disseminated [7].
Accordingly, stage-adapted treatment escalation is recom-
mended by the American Joint Committee on Cancer (AJCC)
[154]. Based on the TMN staging, surgical resection of
localized tumours is combined with radiotherapy, or with
TABLE 9. Recommendations for the management of pro-
gressive multifocal leukoencephalopathy (PML) and other
JCPyV-associated diseases in SOT recipients
In SOT recipients with the diagnosis of possible PML (new onset CNS
deﬁcits, T2-hyperintense, T1-hypointense, preferably subcortical lesions),
CSF should be examined for JCPyV DNA as virological conﬁrmation
(i.e. probable PML) (AIII)
In SOT recipients with possible PML and negative JCPyV DNA results in CSF,
stereotactic biopsy of affected brain lesions should be considered if clinically
indicated to histologically conﬁrm PML (proven PML) or to obtain another
diagnosis (AIII)
In SOT recipients with probable or proven PML, maintenance immunosuppression
should be reduced promptly to a lower limit that permits allograft function and
rapidly enables the restoration of JCPyV-speciﬁc immune control (BIII)
In kidney and pancreas transplant recipients with probable or proven PML,
discontinuation of maintenance immunosuppression and return to functional
organ substitution should be considered to rapidly enable mounting
of JCPyV-speciﬁc immune control (BIII)
In SOT patients with JCPyV-associated granule cell neuronopathy or
encephalopathy, reducing maintenance immunosuppression similar to the
treatment of PML should be considered (BIII)
No recommendations can be made regarding the treatment of SOT recipients
with probable or proven PML using serotonin-uptake inhibitors of the type
mirtazapine, intravenous cidofovir, high-dose intravenous immunoglobulins,
leﬂunomide or brincidofovir (CMX001) (CIII)
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additional radiotherapy of the regional lymph nodes for larger
tumours or deﬁnite lymph node involvement, whereas
chemotherapy is the key approach for metastatic Merkel cell
carcinoma. Overall, the experience of treating SOT recipients
with Merkel cell carcinoma is limited to delineate speciﬁc
recommendations. Expert centres dealing with skin malignan-
cies should be contacted early in the process of diagnosis and
staging and referral of patients considered. Improving the
overall immune function is likely to play a role in the overall
management, but the feasibility and efﬁcacy of this approach is
not documented and highly dependent on the underlying organ
transplant. There is no role of antivirals in the treatment of this
non-replicative disease, but interferon-a treatment for
non-transplanted patients and more speciﬁc drugs aimed at
the viral oncogene–host cell interaction may be future
developments.
Trichodysplasia spinulosa is clinically suspected because of its
characteristic skin features [8]. Proven diagnosis requires skin
biopsies for histopathology and immunohistochemistry, which
is, however, not frequently performed when balancing the
moderate invasiveness against the diagnostic certainty in clear
cases. Given the broader differential diagnosis of digitate
hyperkeratotic diseases [63], collection of the protruding
spiculae for TSPyV NAT is a non-invasive alternative. However,
as TSPyV has been detected in healthy persons, the role of
qualitative TSPyV NAT in diagnosis is not resolved. Treatment
consists of improving immune function, which in SOT recipients
consists of reducing maintenance immunosuppression, ideally
without precipitating acute rejection episodes [8]. There is no
evidence suggesting the preferential reduction of CNIs over the
antiproliferative agent, but given the importance of T-cell
activation, it seems plausible that reducing the CNI has a critical
role in a step-wise approach. Topical antivirals (i.e. cidofovir 1–
3% cream) have been successfully combined with reduced
immunosuppression, without detrimental local or systemic
effects such as renal, haematopoietic or ocular toxicity.
Presumably, the TSPyV actively recruits the host cell DNA
polymerase in the infected cells for effective viral replication.
Thereby, infected cells and the viral effects are presumably
becoming more sensitive than non-infected cells to this high
local concentration of cidofovir. Thus, there is currently little
evidence to recommend speciﬁc approaches for the treatment
of Trichodysplasia spinulosa, but it seems reasonable to consult
an expert in dermatological diseases in SOT.
Conclusions
Human polyomaviruses are a growing challenge in immuno-
compromised patients in view of the increasing number of
different virus species and their diverse disease potential,
including in SOT recipients. The distinction between infection,
replication and disease is not only important for clinical
studies, but also helps to improve diagnosis and management
of probable and proven HPyV disease in clinical practice. The
quality of the clinical evidence and the strength of most
recommendations are presently limited, but are expected to
be improved in the coming years.
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